

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Equality and health inequality impact assessment

GID-HTG10153 MMprofiler for estimating risk in newly diagnosed multiple myeloma

Scoping

1 Have any potential equality issues been identified during the scoping process? If so, what are they?

No potential equality issues related to the technology have been identified.

Several potential equality considerations related to the condition have been identified within the scope of assessing this technology. Key considerations include:

- Cancer is considered a disability under the Equality Act 2010 from the point of diagnosis.
- Multiple myeloma is more common in people 65 years and over and in men.
- Cancer research UK's statistics for myeloma reports that multiple myeloma incidence rates are lower in the Asian ethnic group, higher in the Black ethnic group, and similar in people of mixed or multiple ethnicity compared with the White ethnic group in England.

Age, disability, race and sex are protected characteristics under the Equality Act 2010.

2 Have any potential health inequality issues been identified during the scoping process? If so, what are they?

Multiple myeloma is a relapsing and remitting cancer, and people often have to travel to hospital for repeated treatments over multiple different

treatment cycles in their lifetime. People living in more rural areas or further away from treatment centres may have more difficulty attending regular hospital appointments, which may influence their treatment decisions.

3 What is the preliminary view as to what extent the committee needs to address the potential issues set out in questions 1 and 2?

The committee should consider all potential equality issues and health inequalities when making recommendations.

4 Has any change to the draft scope been agreed to highlight the potential equality or health inequality issues set out in questions 1 and 2 following the scoping workshop?

No changes to the draft scope have been made following the scoping workshop.

5 Has the stakeholder list been updated as a result of additional equality or health inequality issues identified during the scoping process?

No change to the stakeholder list has been made as a result of additional equality or health inequality issues identified during scoping.

Approved by senior responsible officer: Rebecca Albrow

Date: 29/04/2026

Draft guidance (if issued)

6 Have the potential equality issues identified during the scoping process been addressed by the committee? If so, how?

[add answer]

7 Have the potential health inequality issues identified during the scoping process been addressed by the committee? If so, how?

[add answer]

8 Have any other potential equality or health inequality issues been raised in information submitted by stakeholders or in the external assessment report? If so, how has the committee addressed these?

[add answer]

9 Have any other potential equality or health inequality issues been identified by the committee? If so, how has the committee addressed these?

[add answer]

10 Do the preliminary recommendations make it more difficult for a specific group to access the technology than other groups? If so, what are the barriers to, or difficulties with, access for this group?

[add answer]

11 Has the committee made any reasonable adjustments within its recommendations for the equality issues identified? That is, have any adjustments to the recommendations been made to remove or alleviate barriers to, or difficulties with, access to the technology needed to fulfil NICE's obligations to promote equality.

[add answer]

12 Has the committee taken into consideration the health inequality issues in its decision-making? If so, how was this done?

[add answer]

- 13 Have the committee’s considerations of equality and health inequality issues been described in the draft guidance? If so, where?**

[add answer]

Approved by senior responsible officer: [name]

Date: XX/XX/20XX

Final draft guidance (when issued)

- 14 Have any additional potential equality or health inequality issues been raised during consultation on the draft guidance? If so, how has the committee addressed these?**

[add answer]

- 15 Have any additional potential equality or health inequality issues been identified by the committee? If so, how has the committee addressed these?**

[add answer]

- 16 If the recommendations have changed after consultation, do the updated recommendations make it more difficult for a specific group to access the technology than other groups? If so, what are the barriers to, or difficulties with, access for this group?**

[add answer]

- 17 If the recommendations have changed after consultation, has the committee made any other reasonable adjustments in the**

recommendations for the equality issues identified? That is, have any adjustments to the recommendations been made to remove or alleviate barriers to, or difficulties with, access to the technology needed to fulfil NICE’s obligations to promote equality.

[add answer]

18 Has the committee taken into consideration the health inequality issues in its decision-making? If so, how was this done?

[add answer]

19 Have the committee’s considerations of equality and health inequality issues been described in the final draft guidance? If so, where?

[add answer]

Approved by senior responsible officer: [name]

Date: XX/XX/20XX